The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2022 | Updates on ropeginterferon in MPNs
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, shares some updates on the role of ropeginterferon alfa-2b in the treatment of myeloproliferative neoplasms (MPNs), highlighting the efficacy of this agent in comparison to best available therapy (BAT). Prof. Kiladjian further discusses some results from a six-year follow-up study comparing the use of ropeginterferon versus BAT. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Advisory boards for Novartis, Abbvie, BMS, AOP Orphan.
